Advertisement
Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow My Folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pappas, D. J.
Right arrow Articles by Oksenberg, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pappas, D. J.
Right arrow Articles by Oksenberg, J. R.
NEUROLOGY 2010;74:S62-S69
© 2010 American Academy of Neurology

Multiple sclerosis pharmacogenomics

Maximizing efficacy of therapy
Derek J. Pappas, PhD and Jorge R. Oksenberg, PhD

From the Department of Neurology, University of California at San Francisco.

Address correspondence and reprint requests to Dr. Jorge R. Oksenberg, 513 Parnassus Avenue, Room S256, San Francisco, CA 94143-0435 Jorge.Oksenberg{at}ucsf.edu

Genetic polymorphisms and variable expression of drug receptors, metabolizing enzymes, and transporters have been linked to interindividual differences in efficacy and toxicity of many Food and Drug Administration-approved therapeutic agents. In multiple sclerosis, the combination of heterogeneity of disease pathology and significant variation in clinical response to disease-modifying agents necessitates the definition of biomarkers that can a priori predict therapeutic response and define appropriate therapeutic regimens. Pharmacogenomic studies will directly address the question of heterogeneity by analysis of the correlation between different genomic variants and clinical responses to therapy. These studies will include longitudinal designs, maximize clinical response variables, include whole-genome technologies, use large patient cohorts, and require the development of novel mathematical algorithms designed to integrate the wealth of disparate data to identify modest genetic effects and interactions.

ABC = adenosine triphosphate-binding cassette; EAE = experimental autoimmune encephalomyelitis; EDSS = Expanded Disability Status Scale; FDA = Food and Drug Administration; GA = glatiramer acetate; HLA = human leukocyte antigen; IFN = interferon; IL = interleukin; MBP = myelin basic protein; MS = multiple sclerosis; MTX = mitoxantrone; MxA = antiviral-related gene MX1; NAb = neutralizing antibody; PGt = pharmacogenetic; PGx = pharmacogenomics; PML = progressive multifocal leukoencephalopathy; RRMS = relapsing-remitting multiple sclerosis; SNP = single-nucleotide polymorphism; STR = single-tandem repeat; TCR = T-cell receptor; TGF = transforming growth factor; VCAM1 = vascular cell adhesion molecule 1; VLA4 = very late antigen 4; WGA = whole-genome association.

This supplement was supported by an educational grant from Teva Neuroscience. Expert Medical Education contributed to the editorial refinement of this article and to the production of this supplement. Authors may have accepted honoraria for their supplement contributions.

Disclosure: Dr. Pappas reports no disclosures. Dr. Oksenberg is an associate editor of Annals of Neurology.






Advertisement